Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Tumor Necrosis Factor Inhibitors Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Tumor Necrosis Factor Inhibitors Drug Supply by Company

    • 2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume by Company
    • 2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value by Company
    • 2.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Company
    • 2.4 Tumor Necrosis Factor Inhibitors Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Tumor Necrosis Factor Inhibitors Drug Market Status by Category

    • 3.1 Tumor Necrosis Factor Inhibitors Drug Category Introduction
      • 3.1.1 Cimzia (Certolizumab Pegol)
      • 3.1.2 Enbrel (Etanercept)
      • 3.1.3 Humira ( Adalimumab)
      • 3.1.4 Otezla (Apremilast)
      • 3.1.5 Remicade (Infliximab)
      • 3.1.6 Simponi (Golimumab)
    • 3.2 Global Tumor Necrosis Factor Inhibitors Drug Market by Category
      • 3.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Tumor Necrosis Factor Inhibitors Drug Market Status by End User/Segment

    • 4.1 Tumor Necrosis Factor Inhibitors Drug Segment by End User/Segment
      • 4.1.1 Clinic
      • 4.1.2 Hospital
      • 4.1.3 Others
    • 4.2 Global Tumor Necrosis Factor Inhibitors Drug Market by End User/Segment
      • 4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Tumor Necrosis Factor Inhibitors Drug Market Status by Region

    • 5.1 Global Tumor Necrosis Factor Inhibitors Drug Market by Region
      • 5.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume by Region
      • 5.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value by Region
    • 5.2 North America Tumor Necrosis Factor Inhibitors Drug Market Status
    • 5.3 Europe Tumor Necrosis Factor Inhibitors Drug Market Status
    • 5.4 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Status
    • 5.5 Central & South America Tumor Necrosis Factor Inhibitors Drug Market Status
    • 5.6 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Market Status

    6 North America Tumor Necrosis Factor Inhibitors Drug Market Status

    • 6.1 North America Tumor Necrosis Factor Inhibitors Drug Market by Country
      • 6.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Tumor Necrosis Factor Inhibitors Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Tumor Necrosis Factor Inhibitors Drug Market Status

    • 7.1 Europe Tumor Necrosis Factor Inhibitors Drug Market by Country
      • 7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Status

    • 8.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market by Country
      • 8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Tumor Necrosis Factor Inhibitors Drug Market Status

    • 9.1 Central & South America Tumor Necrosis Factor Inhibitors Drug Market by Country
      • 9.1.1 Central & South America Tumor Necrosis Factor Inhibitors Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Tumor Necrosis Factor Inhibitors Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Market Status

    • 10.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Market by Country
      • 10.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Tumor Necrosis Factor Inhibitors Drug Manufacturing Cost Analysis
    • 11.5 Tumor Necrosis Factor Inhibitors Drug Sales Channel and Distributors Analysis
      • 11.5.1 Tumor Necrosis Factor Inhibitors Drug Sales Channel
      • 11.5.2 Tumor Necrosis Factor Inhibitors Drug Distributors
    • 11.6 Tumor Necrosis Factor Inhibitors Drug Downstream Major Buyers

    12 Global Tumor Necrosis Factor Inhibitors Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Category
      • 12.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume Forecast by Category
      • 12.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value Forecast by Category
      • 12.2.3 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Category
    • 12.3 Global Tumor Necrosis Factor Inhibitors Drug Forecast by End User/Segment
      • 12.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by End User/Segment

    13 Global Tumor Necrosis Factor Inhibitors Drug Market Forecast by Region/Country

    • 13.1 Global Tumor Necrosis Factor Inhibitors Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Zydus Cadila
      • 14.1.1 Company Information
      • 14.1.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.1.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 UCB
      • 14.2.1 Company Information
      • 14.2.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.2.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Tsumura
      • 14.3.1 Company Information
      • 14.3.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.3.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Toyama Chemical
      • 14.4.1 Company Information
      • 14.4.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.4.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Simcere Pharmaceutical
      • 14.5.1 Company Information
      • 14.5.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.5.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Shanghai Pharmaceuticals
      • 14.6.1 Company Information
      • 14.6.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.6.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Shanghai CP Guojian Pharmaceutical
      • 14.7.1 Company Information
      • 14.7.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.7.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Sanofi-Aventis
      • 14.8.1 Company Information
      • 14.8.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.8.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Sandoz
      • 14.9.1 Company Information
      • 14.9.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.9.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Samsung Bioepis
      • 14.10.1 Company Information
      • 14.10.2 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 14.10.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Reliance Life Sciences
    • 14.12 PROBIOMED
    • 14.13 Novartis
    • 14.14 Momenta Pharmaceuticals
    • 14.15 MedImmune
    • 14.16 LG Life Sciences
    • 14.17 LEO Pharma
    • 14.18 Janssen Biotech
    • 14.19 Intas Pharmaceuticals
    • 14.20 HanAll Biopharma
    • 14.21 GlaxoSmithKline
    • 14.22 EPIRUS Biopharmaceuticals
    • 14.23 Dexa Medica
    • 14.24 Delenex Therapeutics
    • 14.25 Celltrion
    • 14.26 Celgene Corporation
    • 14.27 CASI Pharmaceuticals
    • 14.28 Bionovis
    • 14.29 AryoGen Biopharma
    • 14.30 Apogenix

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Tumor Necrosis Factor Inhibitors Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Tumor Necrosis Factor Inhibitors Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Cimzia (Certolizumab Pegol)
      Enbrel (Etanercept)
      Humira ( Adalimumab)
      Otezla (Apremilast)
      Remicade (Infliximab)
      Simponi (Golimumab)

      Segmented by End User/Segment
      Clinic
      Hospital
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Zydus Cadila
      UCB
      Tsumura
      Toyama Chemical
      Simcere Pharmaceutical
      Shanghai Pharmaceuticals
      Shanghai CP Guojian Pharmaceutical
      Sanofi-Aventis
      Sandoz
      Samsung Bioepis
      Reliance Life Sciences
      PROBIOMED
      Novartis
      Momenta Pharmaceuticals
      MedImmune
      LG Life Sciences
      LEO Pharma
      Janssen Biotech
      Intas Pharmaceuticals
      HanAll Biopharma
      GlaxoSmithKline
      EPIRUS Biopharmaceuticals
      Dexa Medica
      Delenex Therapeutics
      Celltrion
      Celgene Corporation
      CASI Pharmaceuticals
      Bionovis
      AryoGen Biopharma
      Apogenix
      Buy now